U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. CDER Offices and Divisions
  6. Office of Immunology and Inflammation - Division of Pulmonology, Allergy, and Critical Care (DPACC)
  1. CDER Offices and Divisions

Office of Immunology and Inflammation - Division of Pulmonology, Allergy, and Critical Care (DPACC)

The Division of Pulmonology, Allergy and Critical Care (DPACC) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products intended for the prevention, treatment or diagnosis of conditions including:

  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Idiopathic pulmonary fibrosis (IPF)
  • Acute respiratory distress syndrome (ARDS)
  • Seasonal and perennial allergic rhinitis (SAR, PAR)
  • Chronic idiopathic urticaria (CIU)
  • Cough and cold symptoms (prescription drug products only)
  • Cough inducers (for challenge tests)
  • Hereditary angioedema (HAE)
  • Anaphylaxis
  • Cystic fibrosis (except infections associated with CF)
  • Products for critical care (e.g., epinephrine)
  • Surfactants for infant respiratory distress syndrome (RDS)

Contact Us

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Pulmonology, Allergy and Critical Care
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2300
Fax: (301) 796-9728

Resources



Back to Top